Peer-reviewedCC BYFrontiers in immunology
Immunocytokines in cancer: a safety perspective
- 1Safety Sciences, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca , , ,
- 2Safety Sciences, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca , ,
Related
- Evaluating Pedestrian Crossing Safety: Implementing and Evaluating a Convolutional Neural Network Model Trained on Paired Aerial and Subjective Perspective Images (Vol 11, E42428, 2025)
- One Health perspective on mycotoxins in poultry production: Ecology, toxicological effects, occupational and environmental exposure, food safety risks, and mitigation strategies (2020–2025)
- Nutritional and food safety perspective of plant-forward dietary transitions in Denmark
- Interferon-induced transmembrane proteins in cancer and virus biology: a membrane perspective
- FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
BibTeX
@article{prajapati2026immunocytokines,
title = {{Immunocytokines in cancer: a safety perspective}},
author = {Kushal Prajapati and Catherine Betts and Richard Stebbings},
journal = {Frontiers in immunology},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13673304},
note = {CC BY},
}
RIS
TY - JOUR
TI - Immunocytokines in cancer: a safety perspective
AU - Kushal Prajapati
AU - Catherine Betts
AU - Richard Stebbings
PY - 2026
DA - 2026/10/19
JO - Frontiers in immunology
UR - https://europepmc.org/article/PMC/PMC13673304
SN - 1664-3224
ER -